|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minguet J, Smith KH and Bramlage P:
Targeted therapies for treatment of non-small cell lung
cancer-Recent advances and future perspectives. Int J Cancer.
138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Rourke N, Roqué I, Figuls M, Farré
Bernadó N and Macbeth F: Concurrent chemoradiotherapy in non-small
cell lung cancer. Cochrane Database Syst Rev: CD002140. 2010.
View Article : Google Scholar
|
|
4
|
Johnson DH, Schiller JH and Bunn PA Jr:
Recent clinical advances in lung cancer management. J Clin Oncol.
32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Merschjohann K and Steverding D: In vitro
trypanocidal activity of the anti-helminthic drug niclosamide. Exp
Parasitol. 118:637–640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Li PK, Roberts MJ, Arend RC, Samant
RS and Buchsbaum DJ: Multi-targeted therapy of cancer by
niclosamide: A new application for an old drug. Cancer Lett.
349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan JX, Ding K and Wang CY: Niclosamide,
an old antihelminthic agent, demonstrates antitumor activity by
blocking multiple signaling pathways of cancer stem cells. Chin J
Cancer. 31:178–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Osada T, Chen M, Yang XY, Spasojevic I,
Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA and Lyerly
HK: Antihelminth compound niclosamide downregulates Wnt signaling
and elicits antitumor responses in tumors with activating APC
mutations. Cancer Res. 71:4172–4182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C,
Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of
niclosamide in acute myelogenous leukemia stem cells: Inactivation
of the NF-kappaB pathway and generation of reactive oxygen species.
Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK,
Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X: Niclosamide
overcomes acquired resistance to erlotinib through suppression of
STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12:2200–2212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri
FR, Curran WJ, Shin DM and Deng X: Inhibition of STAT3 by
niclosamide synergizes with erlotinib against head and neck cancer.
PLoS One. 8:e746702013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H, Chen X, Yu Y, Wang Z, Zuo Y, Li S,
Yang D, Hu S, Xiang M, Xu Z and Yu Z: Metformin inhibits the growth
of nasopharyngeal carcinoma cells and sensitizes the cells to
radiation via inhibition of the DNA damage repair pathway. Oncol
Rep. 32:2596–2604. 2014.PubMed/NCBI
|
|
13
|
Xu Z, Zuo Y, Wang J, Yu Z, Peng F, Chen Y,
Dong Y, Hu X, Zhou Q, Ma H, et al: Overexpression of the regulator
of G-protein signaling 5 reduces the survival rate and enhances the
radiation response of human lung cancer cells. Oncol Rep.
33:2899–2907. 2015.PubMed/NCBI
|
|
14
|
Wang AM, Ku HH, Liang YC, Chen YC, Hwu YM
and Yeh TS: The autonomous notch signal pathway is activated by
baicalin and baicalein but is suppressed by niclosamide in K562
cells. J Cell Biochem. 106:682–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fonseca BD, Diering GH, Bidinosti MA,
Dalal K, Alain T, Balgi AD, Forestieri R, Nodwell M, Rajadurai CV,
Gunaratnam C, et al: Structure-activity analysis of niclosamide
reveals potential role for cytoplasmic pH in control of mammalian
target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem.
287:17530–17545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu
D, Pan J, Pei D and Ding K: Identification of niclosamide as a new
small-molecule inhibitor of the STAT3 signaling pathway. ACS Med
Chem Lett. 1:454–459. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
You S, Li R, Park D, Xie M, Sica GL, Cao
Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses
radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee SL, Son AR, Ahn J and Song JY:
Niclosamide enhances ROS-mediated cell death through c-Jun
activation. Biomed Pharmacother. 68:619–624. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rademakers SE, Span PN, Kaanders JH, Sweep
FC, van der Kogel AJ and Bussink J: Molecular aspects of tumour
hypoxia. Mol Oncol. 2:41–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meijer TW, Kaanders JH, Span PN and
Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu YZ, Hogenesch JB and Bradfield CA: The
PAS superfamily: Sensors of environmental and developmental
signals. Annu Rev Pharmacol Toxicol. 40:519–561. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jaakkola P, Mole DR, Tian YM, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl
hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghattass K, Assah R, El-Sabban M and
Gali-Muhtasib H: Targeting hypoxia for sensitization of tumors to
radio- and chemotherapy. Curr Cancer Drug Targets. 13:670–685.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li B and Huang C: Regulation of EMT by
STAT3 in gastrointestinal cancer (Review). Int J Oncol. 50:753–767.
2017.PubMed/NCBI
|
|
25
|
Niu G, Briggs J, Deng J, Ma Y, Lee H,
Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R and Yu H: Signal
transducer and activator of transcription 3 is required for
hypoxia-inducible factor-1alpha RNA expression in both tumor cells
and tumor-associated myeloid cells. Mol Cancer Res. 6:1099–1105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jung JE, Lee HG, Cho IH, Chung DH, Yoon
SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK and Chung MH: STAT3 is
a potential modulator of HIF-1-mediated VEGF expression in human
renal carcinoma cells. FASEB J. 19:1296–1298. 2005.PubMed/NCBI
|
|
27
|
Pan Y, Zhou F, Zhang R and Claret FX:
Stat3 inhibitor Stattic exhibits potent antitumor activity and
induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.
PLoS One. 8:e545652013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adachi M, Cui C, Dodge CT, Bhayani MK and
Lai SY: Targeting STAT3 inhibits growth and enhances
radiosensitivity in head and neck squamous cell carcinoma. Oral
Oncol. 48:1220–1226. 2012. View Article : Google Scholar : PubMed/NCBI
|
